Mutual of America Capital Management LLC Trims Stock Holdings in Insulet Co. (NASDAQ:PODD)

Mutual of America Capital Management LLC lessened its stake in shares of Insulet Co. (NASDAQ:PODD) by 3.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,489 shares of the medical instruments supplier’s stock after selling 329 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Insulet were worth $2,477,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Alecta Tjanstepension Omsesidigt purchased a new stake in Insulet in the 4th quarter worth approximately $53,184,000. Proficio Capital Partners LLC purchased a new stake in shares of Insulet in the fourth quarter valued at $28,422,000. Mn Services Vermogensbeheer B.V. increased its stake in Insulet by 2.2% in the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 27,400 shares of the medical instruments supplier’s stock valued at $7,153,000 after purchasing an additional 600 shares during the last quarter. New York Life Investment Management LLC lifted its position in Insulet by 79.6% during the fourth quarter. New York Life Investment Management LLC now owns 16,854 shares of the medical instruments supplier’s stock worth $4,400,000 after buying an additional 7,471 shares during the period. Finally, Allianz Asset Management GmbH boosted its stake in Insulet by 27.7% in the 4th quarter. Allianz Asset Management GmbH now owns 113,921 shares of the medical instruments supplier’s stock worth $29,741,000 after buying an additional 24,734 shares during the last quarter.

Insider Buying and Selling

In other Insulet news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on PODD shares. Barclays upped their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Raymond James reaffirmed an “outperform” rating and set a $328.00 price target (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Morgan Stanley boosted their price objective on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Royal Bank of Canada started coverage on Insulet in a research report on Thursday. They issued an “outperform” rating and a $340.00 target price on the stock. Finally, Citigroup boosted their price target on Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $292.06.

Insulet Stock Down 3.0 %

Shares of NASDAQ PODD opened at $251.81 on Friday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46. The stock’s 50-day simple moving average is $274.36 and its 200-day simple moving average is $251.98. The firm has a market cap of $17.68 billion, a price-to-earnings ratio of 43.49, a PEG ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. As a group, equities analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.